Evidence & regulatory context
- Mechanism
- ChEMBL not queried for this recombinant adipokine in this run. ClinicalTrials.gov searched: 38 raw hits, ALL measure resistin as a circulating biomarker (probiotic, bariatric, stroke-biomarker, hepatitis C and diabetic-foot studies); NONE administers resistin as an intervention. Zero relevant human trials recorded.
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseIschaemia-reperfusionCerebral (MCAO/stroke)MaleIntracerebroventricular and intraperitoneal10 ug/kg body weight for the intraperitoneal route; intrace…
Model: Middle cerebral artery occlusion (45 min ischaemia followed by 24 h reperfusion), focal cerebral ischaemia/reperfusion
Resistin given by intracerebroventricular or intraperitoneal route reduced infarct volume and neurological deficits after MCAO, lowered PARP-1 cleavage and raised phospho-Akt, with improved balance and muscle strength at 14 days. Neuroprotection was partially reversed by wortmannin, implicating PI3…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.